Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Pandolfo

Showing results (111-120 of 163) with videos related to

Pageof 17
Sort By:
Disease Models & Mechanisms|November 9, 2012
Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxiaAurore Hick, Marie Wattenhofer-Donzé, Satyan Chintawar, et al.
Annals of Neurology|May 21, 2013
Mutations in TNK2 in severe autosomal recessive infantile onset epilepsyYuki Hitomi, Erin L Heinzen, Simona Donatello, et al.
Epilepsia|August 27, 2004
Familial partial epilepsy with variable foci: clinical features and linkage to chromosome 22q12Samuel F Berkovic, Jose M Serratosa, Hilary A Phillips, et al.
Movement Disorders Clinical Practice|October 27, 2018
Standardized Assessment of Hereditary Ataxia Patients in Clinical StudiesBrigitte K Paap, Sandra Roeske, Alexandra Durr, et al.
JCI Insight|December 27, 2019
Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxiaMariana Igoillo-Esteve, Ana F Oliveira, Cristina Cosentino, et al.
Neuroimage|July 28, 2009
Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6Jörg B Schulz, Johannes Borkert, Stefanie Wolf, et al.
Brain : a Journal of Neurology|February 21, 2013
Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6Kathrin Reetz, Ana S Costa, Shahram Mirzazade, et al.
Neurology. Genetics|December 16, 2022
Efficacy and Safety of Leriglitazone in Patients With Friedreich Ataxia: A Phase 2 Double-Blind, Randomized Controlled Trial (FRAMES)Massimo Pandolfo, Kathrin Reetz, Alejandra Darling, et al.
Annals of Neurology|August 28, 2014
Epigenetic therapy for Friedreich ataxiaElisabetta Soragni, Wenyan Miao, Marco Iudicello, et al.
Neurological Research and Practice|December 16, 2020
Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA)Kathrin Reetz, Ralf-Dieter Hilgers, Susanne Isfort, et al.
Pageof 17

Showing results (111-120 of 163) with videos related to

Sort By:
Pageof 17
Disease Models & Mechanisms|November 9, 2012
Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxiaAurore Hick, Marie Wattenhofer-Donzé, Satyan Chintawar, et al.
Annals of Neurology|May 21, 2013
Mutations in TNK2 in severe autosomal recessive infantile onset epilepsyYuki Hitomi, Erin L Heinzen, Simona Donatello, et al.
Epilepsia|August 27, 2004
Familial partial epilepsy with variable foci: clinical features and linkage to chromosome 22q12Samuel F Berkovic, Jose M Serratosa, Hilary A Phillips, et al.
Movement Disorders Clinical Practice|October 27, 2018
Standardized Assessment of Hereditary Ataxia Patients in Clinical StudiesBrigitte K Paap, Sandra Roeske, Alexandra Durr, et al.
JCI Insight|December 27, 2019
Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxiaMariana Igoillo-Esteve, Ana F Oliveira, Cristina Cosentino, et al.
Neuroimage|July 28, 2009
Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6Jörg B Schulz, Johannes Borkert, Stefanie Wolf, et al.
Brain : a Journal of Neurology|February 21, 2013
Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6Kathrin Reetz, Ana S Costa, Shahram Mirzazade, et al.
Neurology. Genetics|December 16, 2022
Efficacy and Safety of Leriglitazone in Patients With Friedreich Ataxia: A Phase 2 Double-Blind, Randomized Controlled Trial (FRAMES)Massimo Pandolfo, Kathrin Reetz, Alejandra Darling, et al.
Annals of Neurology|August 28, 2014
Epigenetic therapy for Friedreich ataxiaElisabetta Soragni, Wenyan Miao, Marco Iudicello, et al.
Neurological Research and Practice|December 16, 2020
Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA)Kathrin Reetz, Ralf-Dieter Hilgers, Susanne Isfort, et al.
Pageof 17